hepatitis C

Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Yahoo
Merck
Zepatier
elbasvir/grazoprevir
hepatitis C
Flag link:
Patent Palooza: One Patent Battle in Hep C, And Another Patent Brawl Brewing On Capitol Hill
Patent Palooza: One Patent Battle in Hep C, And Another Patent Brawl Brewing On Capitol Hill
Motley Fool
patents
hepatitis C
Medivation
Xtandi
Merck
Ionis Pharmaceuticals
Gilead Sciences
Flag link:
How Big of a Deal Are Gilead Sciences Patent Woes?
How Big of a Deal Are Gilead Sciences Patent Woes?
Motley Fool
Gilead Sciences
patents
Merck
Ionis Pharmaceuticals
hepatitis C
Flag link:
Gilead Sciences: ‘Another Pretender to Hepatitis C Throne Seems to Be Suffering the AbbVie Fate’
Gilead Sciences: ‘Another Pretender to Hepatitis C Throne Seems to Be Suffering the AbbVie Fate’
Barron's
Gilead Sciences
hepatitis C
Merck
Zepatier
Harvoni
Flag link:
Patent Payoff? Merck's and Ionis Pharmaceuticals' Take Could Be Tiny
Patent Payoff? Merck's and Ionis Pharmaceuticals' Take Could Be Tiny
Motley Fool
Merck
Gilead Sciences
Ionis Pharmaceuticals
hepatitis C
patents
Harvoni
Sovaldi
Flag link:
Gilead to Pay Merck $200 Million in Damages Over Hepatitis C Drug Patents
Gilead to Pay Merck $200 Million in Damages Over Hepatitis C Drug Patents
WSJ Online
Gilead Sciences
Harvoni
Sovaldi
hepatitis C
Merck
Flag link:
Gilead has taken a lot of hits lately. Here’s what it really has to fear
Gilead has taken a lot of hits lately. Here’s what it really has to fear
Stat
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
Impact Of Merck Litigation On Ionis Pharmaceuticals
Impact Of Merck Litigation On Ionis Pharmaceuticals
Seeking Alpha
Ionis Pharmaceuticals
Merck
Gilead Sciences
patents
hepatitis C
Flag link:
Gilead's CEO: We are appealing the case
Gilead's CEO: We are appealing the case
CNBC
Gilead Sciences
patents
Merck
John Milligan
Harvoni
Sovaldi
hepatitis C
Flag link:
Gilead May Have to Pay Rival Merck Billions in Royalties
Gilead May Have to Pay Rival Merck Billions in Royalties
Fortune
Gilead Sciences
Merck
patents
sofosbuvir
Harvoni
Sovaldi
hepatitis C
Flag link:
Merck wins major victory in hep C patent case against Gilead
Merck wins major victory in hep C patent case against Gilead
BioPharma Dive
Merck
hepatitis C
patents
Gilead Sciences
sofosbuvir
Harvoni
Sovaldi
Flag link:
Gilead And The $3 Billion Merck Issue
Gilead And The $3 Billion Merck Issue
Seeking Alpha
Gilead Sciences
Merck
patents
hepatitis C
Harvoni
Sovaldi
Flag link:
Good news, hep C drugmakers: VA stops rationing your pricey treatments
Good news, hep C drugmakers: VA stops rationing your pricey treatments
Fierce Pharma Marketing
hepatitis C
Veterans Administration
Flag link:
VA to stop restricting hep C drugs, offering them to all infected veterans
VA to stop restricting hep C drugs, offering them to all infected veterans
Fierce Pharma
Veterans Administration
hepatitis C
Gilead Sciences
AbbVie
Flag link:
Gilead (GILD) Stock Gains, Owns 94% of Hepatitis-C Market
Gilead (GILD) Stock Gains, Owns 94% of Hepatitis-C Market
TheStreet.com
Gilead Sciences
Harvoni
Sovaldi
hepatitis C
Flag link:
Inside the $100 million ad blitz for a $1,100-a-pill drug for hepatitis C
Inside the $100 million ad blitz for a $1,100-a-pill drug for hepatitis C
Stat
hepatitis C
drug ads
Harvoni
Gilead Sciences
Flag link:
Gilead, Merck Spar Over Hepatitis C $1,000-Pill Royalties
Gilead, Merck Spar Over Hepatitis C $1,000-Pill Royalties
Bloomberg
Gilead Sciences
Merck
hepatitis C
Sovaldi
Harvoni
Flag link:
Gilead's 3 Most Profitable Lines of Business
Gilead's 3 Most Profitable Lines of Business
Investopedia
Gilead Sciences
Truvada
Sovaldi
Harvoni
hepatitis C
hepatitis B
HIV
Flag link:
Gilead: Hep C Prescriptions Hold at 94% Among New Patients
Gilead: Hep C Prescriptions Hold at 94% Among New Patients
Barron's
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
Will Merck Encroach On Gilead's Harvoni Territory?
Will Merck Encroach On Gilead's Harvoni Territory?
Yahoo/Benzinga
Merck
Gilead
Harvoni
AbbVie
hepatitis C
Viekira Pak
Zepatier
Flag link:

Pages